Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-22T20:35:55.392Z Has data issue: false hasContentIssue false

Chapter 3 - Antipsychotic Medications and Metabolic Syndrome

Published online by Cambridge University Press:  14 October 2021

By
Aoife M. Egan  and
Anne M. Doherty
Edited by
Anne M. Doherty ,
Aoife M. Egan  and
Sean Dinneen
Anne M. Doherty
Affiliation:
University College Dublin
Aoife M. Egan
Affiliation:
Division of Endocrinology and Metabolism, Mayo Clinic, Minnesota, USA
Sean Dinneen
Affiliation:
School of Medicine, National University of Ireland, Galway
Get access

Summary

Antipyschotic medications have benefited countless people with a wide variety of pyschiatric disorders. However, they do have potential to induce metabolic disturbances in a population that is known to have a high risk of cardiovascular disease. This can result in the development of metabolic syndrome and associated complications. There is a strong association between the presence of metabolic syndrome and developing type 2 diabetes. Patients with severe mental illness are at increased risk for metabolic syndrome, diabetes and cardiovascular disease. This is likely due to a number of factors, including higher rates of smoking, poor diet and disordered lifestyle with minimal physical activity. In addition, this population is less likely to receive prompt diagnosis and treatment for modifiable risk factors such as hypertension, dyslipidaemia and prediabetes. Overall, second-generation antipsychotic agents have a stronger association with these adverse effects compared to their first-generation counterparts, and previously untreated patients are at highest risk. With this in mind, healthcare professionals and patients should be well informed on this issue and institute close monitoring and prompt treatment of at-risk individuals.

Keywords

diabetespsychosisschizophreniametabolic syndrome
Type
Chapter
Information
Mental Health, Diabetes and Endocrinology , pp. 19 - 30
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alberti, KGMM, Eckel, RH, Grundy, SM, Zimmet, PZ, Cleeman, JI, Donato, KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640–5.Google Scholar
Ford, ES, Giles, WH, Dietz, WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3): 356–9.Google Scholar
Ford, ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005; 28(11): 2745–9.Google Scholar
Ford, ES, Li, C, Sattar, N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008; 31(9): 1898–904.Google Scholar
Gami, AS, Witt, BJ, Howard, DE, Erwin, PJ, Gami, LA, Somers, VK, Montori, VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49(4): 403–14.CrossRefGoogle Scholar
Kahn, R, Buse, J, Ferrannini, E, Stern, M, American Diabetes Association, European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28(9): 2289–304.Google Scholar
Kahn, R, Buse, J, Ferrannini, E, Stern, M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005; 48(9): 1684–99.Google Scholar
Sundström, J, Vallhagen, E, Risérus, U, Byberg, L, Zethelius, B, Berne, C, et al. Risk associated with the metabolic syndrome versus the sum of its individual components. Diabetes Care. 2006; 29(7): 1673–4.CrossRefGoogle ScholarPubMed
Pramyothin, P, Khaodhiar, L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010; 17(5): 460–6.Google Scholar
Nasrallah, HA, Meyer, JM, Goff, DC, McEvoy, JP, Davis, SM, Stroup, TS, Lieberman, JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006; 86(1–3): 15–22.Google Scholar
Kohen, D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl. 2004; 47: S64–6.Google ScholarPubMed
Mitchell, BD. Clustering of schizophrenia with other comorbidities--what can we learn? Schizophr Bull. 2009; 35(2): 282–3.CrossRefGoogle ScholarPubMed
De Hert, M, Detraux, J, van Winkel, R, Yu, W, Correll, CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2): 114–26.Google ScholarPubMed
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009; 373(9657): 31–41.CrossRefGoogle ScholarPubMed
Tarricone, I, Gozzi, BF, Serretti, A, Grieco, D, Berardi, D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med. 2010; 40(2): 187–200.Google Scholar
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12): 1209–23.CrossRefGoogle ScholarPubMed
Mitchell, AJ, Vancampfort, D, Sweers, K, van Winkel, R, Yu, W, De Hert, M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders – a systematic review and meta-analysis. Schizophr Bull. 2013; 39(2): 306–18.Google ScholarPubMed
Parks, KA, Parks, CG, Yost, JP, Bennett, JI, Onwuameze, OE. Acute blood pressure changes associated with antipsychotic administration to psychiatric inpatients. Prim Care Companion CNS Disord. 2018; 20(4): 18m02299.Google Scholar
Meyer, JM, Koro, CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004; 70(1): 1–17.CrossRefGoogle Scholar
Sasaki, J, Funakoshi, M, Arakawa, K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin Pharmacol Ther. 1985; 37(6): 684–7.Google Scholar
Ghaeli, P, Dufresne, RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996; 53(17): 2079–81.CrossRefGoogle ScholarPubMed
Meyer, JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001; 21(4): 369–74.Google Scholar
Kim, DD, Barr, AM, Fredrikson, DH, Honer, WG, Procyshyn, RM. Association between serum lipids and antipsychotic response in schizophrenia. Curr Neuropharmacol. 2019; 17(9): 852–60.CrossRefGoogle ScholarPubMed
Cai, HL, Tan, QY, Jiang, P, Dang, RL, Xue, Y, Tang, MM, et al. A potential mechanism underlying atypical antipsychotics-induced lipid disturbances. Transl Psychiatry. 2015; 5: e661.Google Scholar
Nasrallah, HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008; 13(1): 27–35.Google Scholar
Kessing, LV, Thomsen, AF, Mogensen, UB, Andersen, PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010; 197(4): 266–71.CrossRefGoogle ScholarPubMed
Baker, RA, Pikalov, A, Tran, Q-V, Kremenets, T, Arani, RB, Doraiswamy, PM. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull. 2009; 42(1): 11–31.Google Scholar
Hammerman, A, Dreiher, J, Klang, SH, Munitz, H, Cohen, AD, Goldfracht, M. Antipsychotics and diabetes: an age-related association. Ann Pharmacother. 2008; 42(9): 1316–22.Google Scholar
Zhang, Y, Liu, Y, Su, Y, You, Y, Ma, Y, Yang, G, et al. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017; 17(1): 373.CrossRefGoogle ScholarPubMed
Holt, RIG. Association between antipsychotic medication use and diabetes. Curr Diab Rep. 2019; 19(10): 96.CrossRefGoogle ScholarPubMed
Ader, M, Kim, SP, Catalano, KJ, Ionut, V, Hucking, K, Richey, JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005; 54(3): 862–71.Google Scholar
Panariello, F, Perruolo, G, Cassese, A, Giacco, F, Botta, G, Barbagallo, APM, et al. Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance. J Cell Physiol. 2012; 227(4): 1485–92.Google Scholar
Alghamdi, F, Guo, M, Abdulkhalek, S, Crawford, N, Amith, SR, Szewczuk, MR. A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes. Cell Signal. 2014; 26(6): 1355–68.Google Scholar
Polcwiartek, C, Vang, T, Bruhn, CH, Hashemi, N, Rosenzweig, M, Nielsen, J. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports. Psychopharmacology (Berl). 2016; 233(21–22): 3663–72.Google Scholar
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004; 27(2): 596–601.CrossRefGoogle Scholar
Shiers, D, Rafi, I, Cooper, SJ, Holt, R. Positive Cardiometabolic Health Resource: an intervention framework for patients with psychosis and schizophrenia. 2014 update (with acknowledgement to the late Helen Lester for her contribution to the original 2012 version), 2014. Available from: www.rcpsych.ac.uk/docs/default-source/improving-care/ccqi/national-clinical-audits/ncap-library/ncap-e-version-nice-endorsed-lester-uk-adaptation.pdf?sfvrsn=39bab4_2Google Scholar
De Hert, M, Dekker, JM, Wood, D, Kahl, KG, Holt, RIG, Möller, H-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009; 24(6): 412–24.Google Scholar
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management, 2014. Available from: www.nice.org.uk/guidance/cg178/chapter/1-recommendationsGoogle Scholar
Mitchell, AJ, Delaffon, V, Vancampfort, D, Correll, CU, De Hert, M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012; 42(1): 125–47.Google Scholar
Holt, RI, Hind, D, Gossage-Worrall, R, Bradburn, MJ, Saxon, D, McCrone, P, et al. Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. Health Technol Assess. 2018; 22(65): 1–160.Google Scholar
Joint British Diabetes Societies for Inpatient Care and Royal College of Psychiatrists. The management of diabetes in adults and children with psychiatric disorders in inpatient settings, 2017. Available from: www.diabetes.org.uk/resources-s3/2017-10/Management of diabetes in adults and children with psychiatric disorders in inpatient settings-August-2017.pdfGoogle Scholar
Dayabandara, M, Hanwella, R, Ratnatunga, S, Seneviratne, S, Suraweera, C, de Silva, VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017; 13: 2231–41.Google Scholar
Bushe, C, Shaw, M, Peveler, RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol. 2008; 22(2 Suppl.): 46–55.Google Scholar
De Hert, M, Peuskens, J, Sabbe, T, Mitchell, AJ, Stubbs, B, Neven, P, et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand. 2016; 133(1): 5–22.Google Scholar
Kane, JM, Meltzer, HY, Carson, WH Jr, McQuade, RD, Marcus, RN, Sanchez, R, Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007; 68(2): 213–23.Google Scholar
Holt, RI, Peveler, RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2011; 74(2): 141–7.CrossRefGoogle ScholarPubMed
Stroup, TS, Gray, N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018; 17(3): 341–56.Google Scholar
Kane, JM, Correll, CU, Goff, DC, Kirkpatrick, B, Marder, SR, Vester-Blokland, E, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009; 70(10): 1348–57.Google Scholar
Costa, AM, Lima, MS, Mari, JdJ. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J. 2006; 124(5): 291–7.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×